NEW YORK, Aug. 6, 2012 /PRNewswire/ -- Faruqi &
Faruqi, LLP, a leading national securities law firm, is
investigating potential securities fraud at AEterna Zentaris Inc.
("AEterna" or the "Company") (NasdaqGM: AEZS).
(Logo:
http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )
The investigation focuses on whether the Company and its
executives violated federal securities laws by failing to disclose
in a timely manner that AEterna's drug perifosine was not effective
in treating colorectal cancer.
On April 2, 2012, AEterna
announced that the Phase 3 "X-PECT" (Xeloda® and Perifosine
Evaluation in Colorectal cancer Treatment) clinical trial
evaluating perifosine and capecitabine (Xeloda®) in patients with
refractory advanced colorectal cancer did not meet the primary
endpoint of improving overall survival versus capecitabine and
placebo. As a result of this news, the Company's stock plummeted
$1.41 per share to close at
$0.73 per share on April 2, 2012, a one-day decline of approximately
66% on high volume.
Request more information now by clicking here:
www.faruqilaw.com/AEZS
Take Action
If you purchased AEterna securities and would like to discuss
your legal rights, visit www.faruqilaw.com/AEZS. You can also
contact us by calling Richard
Gonnello or Francis
McConville toll free at 877-247-4292 or at 212-983-9330 or
by sending an e-mail to rgonnello@faruqilaw.com or
fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also
encourages anyone with information regarding AEterna's conduct to
contact the firm, including whistleblowers, former employees,
shareholders and others.
Attorney Advertising. The law firm responsible for this
advertisement is Faruqi & Faruqi, LLP
(www.faruqilaw.com). Prior results do not guarantee or
predict a similar outcome with respect to any future matter.
We welcome the opportunity to discuss your particular case.
All communications will be treated in a confidential matter.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello,
Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP